Recently, Dr. Richard Finn announced promising results of a JCCC clinical trial he led to test a new combination therapy that could benefit 60% of ALL breast cancer patients, specifically those with ER-positive (ER+), HER2-negative (HER2-) breast cancer.
The laboratory research associated with this trial was completely funded by philanthropic gifts.
Watch Dr. Finn describe the impact of this research in this 2-minute video.
Dr. Finn's clinical trial focused on extremely ill patients with advanced ER+, HER2- breast cancer that was resistant to standard treatment. Their disease was rapidly spreading at the time of their enrollment, yet they responded to the combination therapy with an unprecedented increase in progression-free survival or PFS (the length of time a patient is on treatment without tumor growth) and no significant side effects. The median PFS for the patients on combination therapy was 26.1 months, more than 3 times longer than the PFS for patients who received the standard therapy.
These results validate the JCCC's translational research approach--identifying important targets of cancer therapy in the lab and developing them into treatments.
Philanthropic support accelerated this project, helping JCCC researchers to turn a lab discovery into a new therapy for the most common subtype of breast cancer in less than six years. Nearly 150,000 new cases of ER+, HER2- breast cancer are diagnosed each year in the United States.
With continued philanthropic support, we expect our research efforts to produce similar impacts in other cancers. Be a Cancer Hero and make a gift today to support JCCC research.